MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$1,476K
Net Income
-$13,035K
Net Profit Margin
-883.13%
EPS
-$0.3
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
1,476
464
303
258
Research and development
10,906
13,158
14,223
15,915
General and administrative
3,918
4,029
5,626
4,396
Total operating expenses
14,824
17,187
19,849
20,311
Loss from operations
-13,348
-16,723
-19,546
-20,053
Interest income, net
319
453
647
630
Other income, net
-
3
-
-
Other income
-1
-
0
6
Loss before income taxes
-13,030
-16,267
-18,899
-19,417
Income taxes
0
7
0
0
Net loss
-13,030
-16,274
-18,899
-19,417
Unrealized loss on marketable securities
-5
-15
-1
13
Comprehensive loss
-13,035
-16,289
-18,900
-19,404
Basic EPS
-0.3
-0.384
-0.45
-0.54
Diluted EPS
-0.3
-0.384
-0.45
-0.54
Basic Average Shares
42,980,174
42,381,474
42,234,405
35,749,160
Diluted Average Shares
42,980,174
42,381,474
42,234,405
35,749,160
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$13,035K
(13.67%↑ Y/Y)
Net loss
-$13,030K
(13.68%↑ Y/Y)
Unrealized loss on
marketable securities
-$5K
(-25.00%↓ Y/Y)
Loss before income
taxes
-$13,030K
(13.68%↑ Y/Y)
Interest income, net
$319K
(-55.13%↓ Y/Y)
Loss from operations
-$13,348K
(15.54%↑ Y/Y)
Total revenues
$1,476K
(504.92%↑ Y/Y)
Other income
-$1K
(50.00%↑ Y/Y)
Total operating
expenses
$14,824K
(-7.63%↓ Y/Y)
Research and development
$10,906K
(-6.61%↓ Y/Y)
General and
administrative
$3,918K
(-10.34%↓ Y/Y)
Buy us a coffee
Vistagen Therapeutics, Inc. (VTGN)
Vistagen Therapeutics, Inc. (VTGN)